ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Myositis"

  • Abstract Number: 1163 • ACR Convergence 2024

    Characteristics of Interstitial Lung Disease Progressors in an Antisynthetase Autoantibody-Positive Population

    Aurélie Mourot1, Beatrice Panuta1, Juliette Charbonneau1, Ange Mounkam Ngeuleu1, Caroline Vo2, Eric Rich3, Josiane Bourré-Tessier3, Edith Villeneuve3, Hélène Manganas3, Andréanne Gauthier3, Julie Morisset3, Sabrina Anh-Tu Hoa3 and Océane Landon-Cardinal3, 1University of Montreal, Montreal, QC, Canada, 2Hôpital Charles Lemoyne, Montreal, QC, Canada, 3Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada

    Background/Purpose: Antisynthetase syndrome (ASSD) is characterized by interstitial lung disease (ILD), myositis, polyarthritis, Raynaud’s phenomenon, dermatomyositis-like rash and mechanic’s hands. ILD may present with isolated…
  • Abstract Number: 1734 • ACR Convergence 2024

    Safety and Efficacy Data from a Phase I Trial of Umbilical Lining-Derived Stem Cells (ULSC) in Adult Dermatomyositis/Polymyositis

    Michael R Bubb`1, Eileen Handberg1, Rafael Gonzalez2, Blas Betancourt1, J. Nicole Bostick1, Sarah Long1, Keith March1 and Carl Pepine1, 1University of Florida, Gainesville, FL, 2Restem, LLC, Corona, CA

    Background/Purpose: Mesenchymal stem/stromal cells are self-renewing, multi-potent stromal cells which act as modulators of immune responses. Umbilical cord-derived mesenchymal stromal cells, a classification of cells…
  • Abstract Number: 2076 • ACR Convergence 2024

    Comparing the Efficacy of Conventional Immunosuppression and Rituximab in Anti-SRP Myositis: Insights from a Tertiary Care Centre Experience

    ABHILASHA ARVIND MANWATKAR1, Ajith Sivadasan2, adinair Vijakrishnan2, John Antony Jude Prakash3, chandhu aS4, JOHN KUMAR DAS5, Meera S N2, illiasul Ibad k2 and JOHN MATHEW1, 1christian medical college, vellore, Tamil Nadu, India, 2Christian Medical College, vellore, 3Chritian Medical College, Vellore, 4CMC Vellore, Vellore, Tamil Nadu, India, 5Christian Medical College, Vellore, India

    Background/Purpose:  There is a relative scarcity of studies on the effective management of Anti-signal recognition particle (anti-SRP)  myositis. Recent consensus on anti-SRP myositis shows that…
  • Abstract Number: 2667 • ACR Convergence 2024

    Anti-Mi2 Autoantibodies in Dermatomyositis Patients Also Recognize Autoimmune Regulator (AIRE) Protein

    Jon Musai1, Sahana Jayaraman2, katherine Pak3, Iago Pinal-Fernandez4, Sandra Muñoz-braceras5, Maria Casal-Dominguez6, Eric Cho5, Fa'alataitaua Fitisemanu5, jose milisenda7, Lisa Rider8, Adam Schiffenbauer3, Albert Selva-O’Callaghan9, Thomas E Lloyd10, Lisa Christopher-Stine11, Peter Burbelo12, Benjamin Larman11 and Andrew Mammen13, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3National Institutes of Health, Bethesda, MD, 4NIAMS/National Institutes of Health, Bethesda, MD, 5National Institute of Arthritis and Musculoskeletal and Skin Disease, Bethesda, MD, 6NIAMS, NIH, Bethesda, MD, 7Hospital Clinic de Barcelona, Barcelona, Spain, 8NIEHS, NIH, Garrett Park, MD, 9Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, 10Johns Hopkins University School of Medicine, Lutherville, MD, 11Johns Hopkins University, Baltimore, MD, 12National Institute of Dental and Craniofacial Research, Bethesda, MD, 13NIH, Bethesda, MD

    Background/Purpose: Many myositis patients have myositis-specific autoantibodies (MSA) that define unique clinical phenotypes. For instance, dermatomyositis (DM) patients with anti-Mi2 autoantibodies have weaker muscles, higher…
  • Abstract Number: 0334 • ACR Convergence 2024

    Normal Creatine Kinase in Idiopathic Inflammatory Myopathies- Patient Characteristics and Disease Activity

    shiri keret1, Tanya Chandra2, Lisa Kaly3, Raisa Silva4, Eugenia Gkiaouraki5, Nantakarn Pongtarakulpanit6, shreya Sriram5, Rajesh Gopalarathinam7, Siamak Mogahadam6, Chester Oddis6 and Rohit Aggarwal8, 1Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, 2University of Pittsburgh Medical Center, Pittsburgh, PA, 3Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Haifa, Israel, 4Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 5Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 6Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Division of Rheumatology, Wrightington Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Wigan, United Kingdom, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: Creatine kinase (CK) is an important biomarker for the diagnosis and monitoring of Idiopathic Inflammatory Myopathies (IIM). However, in some cases, CK levels might…
  • Abstract Number: 1143 • ACR Convergence 2024

    Epidemiology and Spectrum of Idiopathic Inflammatory Myopathies in Individuals of Sub-Saharan Ancestry: Data from the Tertiary Care Center of the Caribbean Island of Martinique

    Benoit Suzon1, Rachel Robert1, Fabienne Louis-sidney2, Arthur Felix1, Illitch Coco-Viloin1, Florence Moinet3, Rodolphe Cougnaud1, Rémi Bellance1, Emmanuelle Amazan1, Emma pierrisnard1, Moustapha Agossou1, Christophe Deligny4 and Aurore Abel1, 1University Hospital of Martinique, Fort-de-France, Martinique, 2University Hospital Martinique, Fort De France, Martinique, 3University Hospital of Martinique, Fort de France, France, 4University Hospital of Martinique - National reference center for autoimmune disease, Internal Medicine, Fort-de-France, Martinique

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are heterogeneous systemic autoimmune diseases with a worldwide incidence ranging from 0.116 to 1.9 and a prevalence from 2.4 to…
  • Abstract Number: 1164 • ACR Convergence 2024

    IVIG Treatment Duration in Immune-mediated Necrotizing Myopathy and a Possible Association of Vacuolar Changes with Black/African American Female Patients

    Asim Mohamed1, Liron Caplan2 and Melissa Griffith3, 1PGY5, Aurora, CO, 2Rocky Mountain Regional VAMC, Aurora, CO, 3University of Colorado, Aurora, CO

    Background/Purpose: Immune Mediated Necrotizing Myopathy (IMNM) is a debilitating but understudied entity.  Correlations of demographic and clinical features with pathological findings remain underexplored.  In addition,…
  • Abstract Number: 1735 • ACR Convergence 2024

    High-Intensity Interval Training Outperforms Moderate Exercise in Aerobic Capacity for Recent-Onset Idiopathic Inflammatory Myopathies: A Randomized Controlled Trial

    Kristofer Andreasson1, Cecilia Leijding1, Maryam Dastmalchi2, Antonella Notarnicola3, Stefano Gastaldello1, Heléne Sandlund2, Daniel Andersson4, Ingrid Lundberg5 and Helene Alexanderson2, 1Karolinska Institutet, Stockholm, Sweden, 2Karolinska University hospital, Stockholm, Sweden, 3Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 4Karolinska Institutet, Solna, Sweden, 5Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Exercise is a recognized adjunctive therapy for patients with idiopathic inflammatory myopathies (IIM), enhancing physical capacity and reducing inflammation. Hitherto, moderate-to-intensive exercise has been…
  • Abstract Number: 2077 • ACR Convergence 2024

    Comparison of Janus Kinase Inhibitors to Block the Type I and II Interferon Pathways in Human Myoblasts

    Travis Kinder and James Inglese, National Institutes of Health, Rockville, MD

    Background/Purpose: The family of Janus kinases (JAK1, JAK2, JAK3, TYK2) mediate signal transduction from cytokine receptors through phosphorylation and activation of intracellular signaling pathways and…
  • Abstract Number: 2668 • ACR Convergence 2024

    Do Levels of anti-Jo1 Autoantibodies Have a Prognostic Role? Longitudinal Assessment of anti-Jo1 and HisRS Protein Levels in a Cohort of anti-Jo1 Positive Patients with Anti-synthetase Syndrome

    Silvia Cavalli1, Fabricio Espinosa-Ortega2, Ryan A. Adams3, Lauren Guy3, Charlotta Preger4, Càtia Fernandes-Cerqueira5, Roberto Caporali6, Ingrid Lundberg7 and Antonella Notarnicola8, 1University of Milan, Milan, Milan, Italy, 2Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet; Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, 3aTyr Pharma, 3545 John Hopkins Court, Suite 250, San Diego, CA, 4Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet;5Structural Genomics Consortium, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, 54Dcell, Montrueil, Ile-de-France, France, 6Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, 7Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 8Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden

    Background/Purpose: The anti-Jo1 autoantibody (aJo1), targeting the histidyl-tRNA synthetase (HisRS) protein, is the most common diagnostic biomarker of the anti-synthetase syndrome (ASSD). So far, conflicting…
  • Abstract Number: 0288 • ACR Convergence 2023

    Proinflammatory Bioactive Lipid Mediators (BLM) Are Associated with Worse Anti-Oxidant Function of High Density Lipoproteins (HDL) in Patients with Idiopathic Inflammatory Myopathies (IIM)

    Sangmee Bae1, Ani Shahbazian1, Jennifer Wang2, Dawoud Sulaiman3, David Meriwether4, srinivasa Reddy5 and Christina Charles-Schoeman6, 1UCLA Rheumatology, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, CA, 3UCLA Cardiology, Los Angeles, CA, 4UCLA Digestive Diseases, Los Angeles, CA, 5UCLA Department of Molecular and Medical Pharmacology, Los Angeles, CA, 6UCLA Medical Center, Santa Monica, CA

    Background/Purpose: Lipid oxidation products produced by artery wall cells under oxidative stress not only regulate immune responses, but their accumulation in HDL are shown to…
  • Abstract Number: 0748 • ACR Convergence 2023

    Assessment of Myositis-related Interstitial Lung Disease by ⁶⁸ Ga-DATA.SA.FAPi PET/CT

    Kastriot Kastrati1, Thomas S Nakuz2, Oana C Kulterer2, Stephan Blüml3, Michael Bonelli3, Irina Gessl4, Hans-Peter Kiener3, Werner Langsteger2, Daniel Mrak3, Florian Prayer5, Helmut Prosch5, Elisabeth Simader3, Tatjana Traub-Weidinger2, Daniel Aletaha6, Helga Radner7, Marcus Hacker2 and Peter Mandl3, 1Dept of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna (Austria), Vienna, Austria, 2Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria, 3Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 4Department of Rheumatology, Medical University of Vienna, Vienna, Austria, 5Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, 6Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, 7Division of Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of idiopathic inflammatory myopathies (IIM) ranging up to 78% in IIM and is a key contributor…
  • Abstract Number: 1170 • ACR Convergence 2023

    Damage Accrual in Idiopathic Inflammatory Myopathies: Data from a Monocentric Cohort and Impact on Patients’ Quality of Life

    Chiara Cardelli1, Simone Barsotti2, Elenia Laurino1, Michele Diomedi1, Federico Fattorini1, Alessandra Tripoli1, Linda Carli1 and Marta Mosca1, 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 2Internal Medicine, Ospedale di Livorno, Pisa, Italy

    Background/Purpose: Although the prognosis of Idiopathic Inflammatory Myopathies (IIMs) has noticeably improved over time, their chronicity may still expose a considerable number of patients to…
  • Abstract Number: 1945 • ACR Convergence 2023

    Case Series of 6 Patients Exhibiting Myositis as a Rheumatologic Adverse Events Related to Cancer Immunotherapy in Two Spanish Hospitals

    Arturo Llobell1, Inigo Gonzalez-Mazon2, carmen secada3, Adrian Martin-Gutierrez3, Almudena García-Castaño3, Enrique Gallardo4, Soledad Retamozo5, Antonio Gomez-Centeno6, Luis Fernandez-Morales4, Jordi Gratacos Masmitja7 and Ricardo Blanco8, 1Parc Tauli University Hospital, Barcelona, Spain, 2Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Parc Taulí University Hospital, Sabadell, Spain, 5Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Barcelona, Spain, 6Parc Taulí Hospital Universitari, Sabadell, Spain, 7University Hospital Parc Taulí, Sabadell, Spain, 8Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Myositis is a rare inflammatory complication associated with immune related adverse events (irAE) of immune checkpoints inhibition (ICI) immunotherapy1. It is characterized by musculoskeletal…
  • Abstract Number: 1967 • ACR Convergence 2023

    Infectious Myopathies in an Urban Inflammatory Idiopathic Myopathy Cohort: Frequency and Impact on Disease Course and Treatment

    Ana Valle1, Talia Meisel1, Xianhong Xie2 and Shereen Mahmood3, 1Montefiore Medical Center, Bronx, NY, 2Albert Einstein College of Medicine, Bronx, NY, 3Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY

    Background/Purpose: Over the last few decades, it has been established that multiple infections can mimic idiopathic inflammatory myopathies (IIM). HIV, HTLV-1, and Lyme disease are…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology